AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.
Source: MarketWatch
12. February 2024 14:09
AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.
Source: MarketWatch